AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
29.8 C
New York
Friday, September 4, 2026

Tag: biologics

newssourceFORcompanyinformationcontent1releasesmarket

China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the...

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited

Transaction Expected to Close in the Coming Days

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14,...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiologics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers